Search

You searched for "Blindness"

1031 results found

Diabetes macular oedema in pregnancy self-resolving postpartum

1 October 2021 | | EYE - Vitreo-Retinal, EYE - Imaging, EYE - General
*Equally contributing co-first authors. Diabetic macular oedema (DMO) is a common clinical presentation to ophthalmology clinics. Ample evidence exists for management of DMO in non-pregnant patients. However, there is a paucity of evidence on the optimal management of DMO in...

In vivo confocal microscopy, principles and use in keratitis Part 1: Principles

1 April 2018 | | EYE - Cornea, EYE - Imaging
In 1968 Maurice introduced the concept of high powered specular microscopy, it was in that very year that the first scanning confocal microscope was proposed. Marvin Minsky developed the first confocal microscope in 1955 named the ‘double focusing scanning microscope’....

Understanding spaceflight-associated neuro-ocular syndrome (SANS): what do we know?

2 August 2022 | | EYE - Oculoplastic, EYE - General
Introduction Formerly known as visual impairment and intracranial pressure syndrome (VIIP), space-related neuro-ocular syndrome (SANS) is defined by a collection of ophthalmic and neurological findings in astronauts after long-term spaceflight [1]. Changes in the eyeball, such as hyperopic shift, during...

AI & Oculomics: a new section for Eye News

2 February 2024 | | EYE - General
Inaugurating this new regular section on the exciting landscape of AI and oculomics, we provide an overview which delves into the historical context and the etymology of this field, reviews the current state of play and contemplates possibilities and hopes...

Management of a giant pigment epithelium detachment with transition from half- to full-dose aflibercept

2 March 2026 | | EYE - Imaging, EYE - Vitreo-Retinal
This case report describes the management of a giant pigment epithelial detachment (PED) in neovascular age-related macular degeneration (nAMD) using half-dose aflibercept. An 80-year-old woman presented with a huge PED (maximum height 1338µm) and multiple risk factors for retinal pigment...

Ultra-widefield imaging in glaucoma: Documenting hypotony-related choroidal effusions after microshunt surgery

3 April 2026 | | EYE - Glaucoma, EYE - Imaging
Ultra-widefield (UWF) imaging provides extended visualisation of the posterior segment beyond the traditional 30–50° field of view. It captures a broad view of the posterior pole and periphery in a single, quick, non-mydriatic acquisition. While its role in diabetic retinopathy...

Understanding amniotic membrane grafts

1 June 2019 | | EYE - Cornea, EYE - General
Safa Elhassan gives a brief review of amniotic membrane grafts and their application in theatre and clinic-based settings. Amniotic membrane (AM) transplant has been an established adjuvant treatment for many corneal, conjunctival and scleral disorders in ophthalmic clinical practice with...

Optic nerve swelling – your survival guide (part 1)

1 August 2017 | | EYE - Neuro-ophthalmology
Assessment of optic nerve appearance and functions is a daily routine in neuro-ophthalmology. Following a recent high profile court case there has been a significant increase in the amount of referral to ophthalmology departments to assess the optic nerve and...

NICE drugs: an update on what’s good to go

1 June 2014 | | EYE - Neuro-ophthalmology, EYE - Vitreo-Retinal
Treatment options recommended by the National Institute for Health and Care Excellence (NICE) must be readily available for use in the NHS of England and Wales. This article provides an overview of recent guidance from NICE and summary advice issued...

Advances and developments in medical retina

1 February 2019 | | EYE - Vitreo-Retinal, EYE - General
The author provides an update on late breaking clinical trial results in neovascular age-related macular degeneration (nAMD) and presentations on diabetes management from the American Academy of Ophthalmology Retina Subspecialty Day, held during the Academy’s annual meeting in Chicago, October...

Broadening of treatment options for potentially blinding retinal conditions

2 August 2022 | | EYE - General
Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...

Update on emerging therapies for age-related macular degeneration

4 December 2023 | | EYE - Vitreo-Retinal
The 23rd European Society of Retina Specialists (EURETINA) Congress, held in Amsterdam, the Netherlands, provided a timely update on anti-complement therapy for geographic atrophy and emerging investigational therapies for neovascular age-related macular degeneration. Anti-complement therapy for geographic atrophy Geographic atrophy...